Recombinant Mouse Mucin-13 (Muc13)

What is Mouse Mucin-13 and how does it differ from human MUC13?

Mouse Mucin-13 (Muc13) is a cell surface glycoprotein that belongs to the transmembrane mucin family. Both human and mouse variants serve as components of the mucosal immune system, providing an initial barrier against infections. While they share functional similarities, there are structural differences in their glycosylation patterns and tissue distribution. Human MUC13 has been more extensively studied in cancer contexts, particularly in ovarian, colorectal and liver cancers, while mouse Muc13 has been valuable in modeling stress-related intestinal changes and infection responses .

What are the primary tissue expression patterns of Muc13 in mice?

Mouse Muc13 is predominantly expressed in epithelial tissues, with highest expression in the gastrointestinal tract, particularly in the small and large intestines. Research has demonstrated that Muc13 expression can be detected across different intestinal segments, with regional variations. Unlike some other mucins that show restricted expression patterns, Muc13 has been detected more broadly in mucosal tissues, making it an important marker for studying mucosal immunity in mouse models .

What is the molecular structure and key functional domains of recombinant Muc13?

Recombinant Muc13 typically contains:

• An extracellular domain with heavily glycosylated regions

• A transmembrane domain

• A cytoplasmic tail containing phosphorylation sites for signaling

These structural components allow Muc13 to mediate cell-surface interactions, participate in signal transduction, and contribute to mucosal barrier function. The glycosylated regions are particularly important as they facilitate interactions with microbiota and potential pathogens in the intestinal environment .

What expression systems are recommended for producing functional recombinant mouse Muc13?

For producing functional recombinant mouse Muc13, researchers have successfully employed:

• Mammalian expression systems: HEK293 or CHO cells are preferred for proper post-translational modifications, especially glycosylation patterns essential for Muc13 function

• Baculovirus-insect cell systems: Useful for higher yield while maintaining reasonable glycosylation

Based on methodologies reported in studies developing MUC13 immunoassays, the expression system selection should prioritize proper folding and post-translational modifications over yield. Researchers have successfully developed recombinant MUC13 proteins for the development of monoclonal antibodies and ELISA systems, suggesting that similar approaches could be effective for mouse Muc13 .

What purification strategies yield the highest purity recombinant Muc13?

Optimal purification of recombinant Muc13 typically involves multi-step approaches:

• Initial capture using affinity chromatography (His-tag or antibody-based)

• Intermediate purification with ion exchange chromatography

• Polishing step using size exclusion chromatography

When developing immunoassays for MUC13, researchers have employed purification strategies that maintain the protein's native conformation, which is crucial for subsequent antibody development and assay validation. Special attention should be paid to minimize proteolytic degradation during the purification process by including appropriate protease inhibitors .

How can researchers validate the functional activity of recombinant Muc13?

Validation of recombinant Muc13 functionality should include:

• Western blot analysis: Confirming correct molecular weight and antibody recognition

• Glycosylation analysis: Verifying proper post-translational modifications using glycan-specific stains or mass spectrometry

• Binding assays: Testing interaction with known Muc13 binding partners

• Cell-based assays: Evaluating biological activity in relevant cell lines (intestinal epithelial cells)

Researchers developing MUC13 ELISA systems have validated their recombinant proteins through careful characterization of antibody specificity and analysis of protein secretion in cell culture supernatants, providing methodological approaches that can be adapted for mouse Muc13 .

How is Muc13 involved in infection models, particularly Plasmodium hepatic infection?

Muc13 has been identified as a critical host factor in Plasmodium infection models:

• During Plasmodium exoerythrocytic hepatic-stage infection, Muc13 is strongly upregulated

• The protein colocalizes with parasite biomarkers such as UIS4 and HSP70

• Muc13 expression distinguishes infected cells from adjacent uninfected cells

• This upregulation pattern is conserved across Plasmodium species (both P. berghei and P. vivax)

These findings suggest Muc13 plays a role in host-parasite interactions during malaria infection. The protein's upregulation can be used as a biomarker for infected hepatocytes and potentially for screening compounds that inhibit parasite replication .

What role does Muc13 play in stress-induced intestinal microbiome dysbiosis?

Research has demonstrated that Muc13 serves as a critical link between psychological stress and intestinal microbiome changes:

• Chronic stress exposure selectively reduces Muc13 expression across intestinal segments

• This reduction appears to be specific to Muc13, as other mucins (Muc1, Muc2, Muc4, Muc17) were not similarly affected

• The Muc13 reduction precedes microbiome composition changes rather than being a consequence of them

• Experimental models confirm that microbiome transfer from stressed to non-stressed mice does not alter Muc13 expression

These findings position Muc13 as an upstream mediator of stress-induced microbiome changes, suggesting its potential as a therapeutic target for stress-related intestinal disorders .

How can recombinant Muc13 be utilized in cancer research applications?

Recombinant Muc13 has several applications in cancer research:

• Antibody development: Producing anti-Muc13 antibodies for diagnostic and therapeutic applications

• Biomarker validation: Evaluating Muc13 as a serum biomarker for various carcinomas

• Imaging probe development: Creating radioimmunoconjugates for cancer detection

Studies have demonstrated that MUC13 levels are elevated in 20-30% of patients with ovarian, liver, and lung cancers, and in 70% of patients with active cutaneous melanoma. This suggests that recombinant Muc13 and its antibodies could be valuable tools for developing diagnostic assays and targeted therapies .

What imaging techniques are most effective for visualizing Muc13 in tissue samples?

For optimal visualization of Muc13 in tissue samples:

• Immunofluorescence microscopy: Using anti-Muc13 antibodies with fluorescent tags

• Confocal microscopy: For high-resolution subcellular localization

• Dual immunostaining: Combining Muc13 staining with other markers to assess colocalization

In Plasmodium infection studies, immunofluorescence assays have successfully demonstrated Muc13 upregulation and colocalization with parasite markers. Similar approaches can be adapted for other research contexts, including cancer studies .

How can researchers develop radioimmunoconjugates targeting Muc13 for theranostic applications?

Development of Muc13-targeting radioimmunoconjugates involves several key steps:

• Antibody selection: Identifying highly specific anti-Muc13 antibodies

• Conjugation chemistry: Attaching chelators (e.g., desferrioxamine/DFO) to antibodies

• Radiolabeling: Incorporating appropriate radionuclides (e.g., zirconium-89)

• Quality control: Verifying radiochemical purity and yield

• Validation: Testing specificity through cell binding and internalization assays

This approach has been successfully implemented for human MUC13 in colorectal cancer models, where antibodies against MUC13 were conjugated with DFO and radiolabeled with zirconium-89 for PET imaging. The resulting radioimmunoconjugates showed specific uptake in MUC13-positive tumors, demonstrating the feasibility of this approach .

What experimental designs are optimal for studying Muc13 changes in stress models?

For investigating Muc13 alterations in stress models, recommended approaches include:

• Chronic stress protocols: Using unpredictable chronic mild restraint stress (UCMRS) models

• Regional analysis: Examining Muc13 expression across different intestinal segments

• Temporal assessment: Monitoring changes over time to establish causality

• Combined approaches: Integrating gene expression analysis with protein quantification and localization studies

Research has successfully employed qPCR to measure Muc13 transcript levels in different intestinal segments following stress exposure. This approach revealed stress-induced reductions in Muc13 expression that were consistent across multiple intestinal regions .

What are common challenges in detecting endogenous versus recombinant Muc13?

Researchers often encounter several issues when detecting Muc13:

When developing ELISA systems for MUC13 detection, researchers have addressed these challenges through careful antibody selection and validation against cell lines with known MUC13 expression profiles .

How can researchers accurately quantify Muc13 expression changes in disease models?

For accurate quantification of Muc13 changes:

• qPCR: For transcript-level changes, using validated primers spanning exon junctions

• ELISA: For protein-level quantification in tissue lysates or serum

• Flow cytometry: For cell-surface expression analysis

• Western blotting: For total protein assessment with appropriate loading controls

• Image analysis: For quantitative immunohistochemistry with standardized protocols

Studies examining stress-induced changes in Muc13 have successfully employed qPCR to detect significant reductions in expression across intestinal segments. This approach allowed researchers to identify Muc13 as uniquely affected compared to other mucins .

How might Muc13 interact with the intestinal microbiome to influence host physiology?

Current research suggests several potential mechanisms for Muc13-microbiome interactions:

• Muc13 may provide attachment sites for specific bacterial species

• Changes in Muc13 glycosylation patterns could alter bacterial nutrient availability

• Stress-induced reductions in Muc13 appear to precede microbiome composition changes

• These interactions may have downstream effects on intestinal barrier function and immune responses

Studies have demonstrated that stress-induced Muc13 reductions occur before microbiome shifts, suggesting a causal relationship. This positions Muc13 as a potential therapeutic target for conditions involving microbiome dysbiosis .

What are promising therapeutic strategies targeting Muc13 in various disease contexts?

Emerging therapeutic approaches targeting Muc13 include:

• Antibody-based therapies: Using anti-Muc13 antibodies for cancer treatment

• Radioimmunoconjugates: Combining diagnostic imaging with targeted therapy

• Gene therapy approaches: Restoring normal Muc13 expression in stress-related disorders

• Microbiome modulation: Indirect targeting through restoration of beneficial bacteria

Research on MUC13-targeting antibodies conjugated with radionuclides has demonstrated the feasibility of developing theranostic approaches that combine PET imaging with targeted therapy for colorectal cancer .